SAGE News and Press, Sage Therapeutics Inc. From 12/06/22

Zuranolone is being evaluated as a short course, rapid-acting, oral medication for major depressive disorder (MDD) and postpartum depression (PPD) Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced the completion of the rolling submission of a New Drug A...

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the Piper Sandler 34 th Annual Healthcare Conference on Thursday, December 1, 2022, at 8:00 a.m. ET in New...

Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced that the companies will host a joint investor webcast to discuss the planned commercialization approach and opportunity for their investigational product, zuranolone, on Tuesday, December 6 at 8:00 a.m...

Palm Beach, FL – November 14, 2022 – FinancialNewsMedia.com News Commentary – Anti-anxiety drugs are medications that are used to treat anxiety disorders that are mainly used to relieve anxiety and tension, work by reducing the symptoms of anxiety, such as f...

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the Stifel 2022 Healthcare Conference on Wednesday, November 16, 2022, at 10:55 a.m. ET in New York, NY. A...

Sage Therapeutics, Inc. (SAGE) Q3 2022 Earnings Conference Call November 8, 2022 08:00 AM ET Company Participants Helen Rubinstein - Director, IR Barry Greene - Chief Executive Officer Kimi Iguchi - Chief Financial Officer Jim Doherty - Chief Development Offi...

Sage Therapeutics press release ( NASDAQ: SAGE ): Q3 GAAP EPS of -$2.31 misses by $0.11 . Revenue of $1.74M (+20.8% Y/Y) beats by $0.08M . Cash, cash equivalents and marketable securities as of September 30, 2022 were $1.4 billion compared to $1.5 billion at Ju...

Completion of rolling NDA submission for zuranolone in MDD and PPD on track for December 2022 Presented additional data across pipeline programs at key medical congresses including data on zuranolone as an investigational oral, once-daily, 14-day treatment for MDD and PPD ...

Sage Therapeutics ( NASDAQ: SAGE ) on Tuesday has appointed Laura Gault, MD, Ph.D. as Chief Medical Officer. In her new role, Dr. Gault will focus on advancing Sage’s current and emerging product pipeline through all stages of development. In her previ...

Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the appointment of Laura Gault, MD, Ph.D. as Chief Medical Officer. In her new role, Dr. Gault will focus on advancing Sage’s current and emer...